SCHEMBL23769296

SCHEMBL23769296

CCCc1nc(N2CC3CC3C2)ncc1C(=O)OCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.57
PIK3CD O00329 1/20 0.43
ACACB O00763 1/20 0.42
ALOX15 P16050 3/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 5/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 4/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
NR2F2 P24468 2/20 0.39
MAPK1 P28482 1/20 0.39
RBP4 P02753 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30140742 0.85 MAPT (0.50) PIK3CDACACBALOX15MEN1KMT2A
SCHEMBL21713027 0.85 MAPT (0.50) PIK3CDACACBALOX15MEN1KMT2A
SCHEMBL29906556 0.76 ALDH1A1 (0.45) ACACBMEN1KMT2AALDH1A1GAA
SCHEMBL23754159 0.76 ALDH1A1 (0.45) ACACBMEN1KMT2AALDH1A1GAA
SCHEMBL8395135 0.74 HSP90AA1 (0.72) HSP90AA1MEN1KMT2ATSHRALDH1A1
SCHEMBL1661270 0.73 HSP90AA1 (1.00) HSP90AA1MEN1KMT2ATSHRALDH1A1
SCHEMBL8397025 0.73 HSP90AA1 (0.70) HSP90AA1MEN1KMT2AALDH1A1GAA
SCHEMBL31357739 0.73 HSP90AA1 (0.70) HSP90AA1MEN1KMT2AALDH1A1GAA
SCHEMBL17013519 0.73 PDE5A (0.59) ALOX15MEN1KMT2ATSHRALDH1A1
SCHEMBL22166210 0.72 MAPT (0.49) PIK3CDACACBALOX15MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479827-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-11-25 US disclosed
CN-116120287-B Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein 勃林格殷格翰国际有限公司 2025-01-28 CN disclosed
US-20240076286-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-03-07 US disclosed
US-20240002363-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-01-04 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
CN-116120287-A Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein 勃林格殷格翰国际有限公司 2023-05-16 CN disclosed
CN-115052873-A Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors 勃林格殷格翰国际有限公司 2022-09-13 CN disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed
WO-2021160718-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479827-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 HSP90AA1 3256/4885PIK3CD 3296/4885ACACB 1087/4885
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 HSP90AA1 3256/4885PIK3CD 3296/4885ACACB 1087/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 HSP90AA1 3256/4885PIK3CD 3296/4885ACACB 1087/4885
US-20240002363-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 HSP90AA1 3256/4885PIK3CD 3296/4885ACACB 1087/4885
US-20240076286-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 HSP90AA1 3256/4885PIK3CD 3296/4885ACACB 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.